MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

CRISPR Therapeutics AG

Închisă

SectorSănătate

32.77 -4.07

Rezumat

Modificarea prețului

24h

Curent

Minim

32.17

Maxim

34.17

Indicatori cheie

By Trading Economics

Venit

49M

-37M

Vânzări

34M

35M

EPS

-0.44

Marjă de profit

-106.603

Angajați

393

EBITDA

46M

-60M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+109.36% upside

Dividende

By Dow Jones

Următoarele câștiguri

6 mai 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

3.2B

Deschiderea anterioară

36.84

Închiderea anterioară

32.77

Sentimentul știrilor

By Acuity

54%

46%

323 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bullish Evidence

CRISPR Therapeutics AG Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

26 sept. 2024, 16:08 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

26 sept. 2024, 14:20 UTC

Achiziții, Fuziuni, Preluări

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

11 apr. 2024, 14:46 UTC

Achiziții, Fuziuni, Preluări

Vertex Pharmaceuticals Seeks a Second Act With $4.9B Deal to Buy Alpine Immune -- Barrons.com

Comparație

Modificare preț

CRISPR Therapeutics AG Așteptări

Obiectiv de preț

By TipRanks

109.36% sus

Prognoză pe 12 luni

Medie 71.58 USD  109.36%

Maxim 120 USD

Minim 32 USD

În baza a 20 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruCRISPR Therapeutics AG - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

20 ratings

12

Cumpărare

7

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

32.96 / 36.93Suport & Rezistență

Termen scurt

Weak Bullish Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

323 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe de scădere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.